Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO says

Coloplast A/S Non-GAAP EPS of DKK 6.55, revenue of DKK 7.26B; reaffirms FY 2026 outlook

Coloplast A/S press release (CLPBF): Q3 Non-GAAP EPS of DKK 6.55. Revenue of DKK 7.26B (+4.3% Y/Y). Coloplast delivered Q3 organic growth of 6% and 5%

Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO says

Aug 18 (Reuters) – Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in ​outpatient settings to fall sharply, its finance chief told ‌Reuters on Tuesday. The outpatient business, which accounts for around 20%-30% of Kerecis sales, has “basically collapsed” since the reimbursement changes took effect, CFO Anders Lonning-Skovgaard sai…